Skip to main content
. 2021 Jan 25;6(2):e134601. doi: 10.1172/jci.insight.134601

Figure 1. Echinatin inhibits NLRP3 inflammasome activation in mouse BMDMs and human PBMCs.

Figure 1

(A) The structure of echinatin (Echi) is shown. (B) Cell viability of BMDMs treated with an indicated dose of echinatin was assessed using Cell Counting Kit-8 (CCK-8) or CellTiter-Glo Assay, which is based on quantitation of ATP. (C–F) LPS-primed BMDMs were pretreated with various doses of echinatin and then stimulated with nigericin, cleaved caspase-1 and production of IL-1β (C). Activity of caspase-1 (D), secretion of IL-1β (E), and LDH (F) in SN were assessed. (G–J) LPS-primed human PBMCs were pretreated with various doses of echinatin and then stimulated with nigericin, cleaved caspase-1 and production of IL-1β (C). Activity of caspase-1 (D), secretion of IL-1β (E), and LDH (F) in SN were assessed. Data are expressed as mean ± SEM (n = 3/group, resulting from 3 independent experiments). One-way ANOVA, followed by Dunnett’s post hoc test, was used to assess the differences of multiple groups (B, D–F, and H–J). *P < 0.05, **P < 0.01, ***P < 0.001, ###P < 0.001 compared with control (B) or control with stimulated (D–F, H–J).